Related Experiment Video
Updated: Jul 28, 2026

A Miniaturized Glycan Microarray Assay for Assessing Avidity and Specificity of Influenza A Virus Hemagglutinins
Published on: May 29, 2016
Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a
M Porotto1, O Greengard, N Poltoratskaia
1Department of Pediatrics, Mount Sinai School of Medicine, New York, New York 10029, USA.
Abstract:
The envelope of human parainfluenza virus type 3 (HPF3) contains two viral glycoproteins, the hemagglutinin-neuraminidase (HN) and the fusion protein (F). HN, which is responsible for receptor attachment and for promoting F-mediated fusion, also possesses neuraminidase (receptor-destroying) activity. We reported previously that 4-guanidino-neu5Ac2en (4-GU-DANA) and related sialic acid-based inhibitors of HPF3 neuraminidase activity also inhibit HN-mediated receptor binding and fusion processes not involving neuraminidase activity. We have now examined this mechanism, as well as neuraminidase's role in the viral life cycle, using a neuraminidase-deficient HPF3 variant (C28a) and stable cell lines expressing C28a or wild-type (wt) HN. C28a, which has a wt F sequence and two point mutations in the HN gene corresponding to two amino acid changes in the HN protein, is the first HPF3 variant with insignificant neuraminidase activity. Cells expressing C28a HN did not bind erythrocytes at 4 degrees C unless pretreated with neuraminidase, but no such pretreatment was required for hemadsorption activity (HAD) at 22 or 37 degrees C. HAD was blocked by 4-GU-DANA, attesting to the ability of this compound to inhibit HN's receptor-binding activity. C28a or wt plaque enlargement, a process that involves cell-cell fusion and does not depend on virion release, is diminished by the presence of 4-GU-DANA, confirming the inhibitory effect of 4-GU-DANA on the fusogenic function of C28a HN. In C28a-infected cell monolayers, virion release and thus multicycle replication are severely restricted. This defect was corrected by supplementation of exogenous neuraminidase and also by the addition of 4-GU-DANA; neuraminidase destroys the receptors whereby newly formed C28a virions would remain attached to the cell surface, whereas 4-GU-DANA prevents the attachment itself, obviating the need for receptor cleavage. In accord with the ability of 4-GU-DANA to prevent attachment, the neuraminidase inhibitory effect of 4-GU-DANA on wt HPF3 did not diminish virion release into the medium. Thus, it is by inhibition of viral entry and syncytium formation that sialic acid analogs like 4-GU-DANA may counteract wt HPF3 infection.
Insights
Sialic acid analogs like 4-guanidino-neu5Ac2en (4-GU-DANA) inhibit human parainfluenza virus type 3 (HPF3) by blocking viral entry and cell fusion. This study reveals how these compounds counteract HPF3 infection.
Area of Science:
- Virology
- Molecular Biology
- Biochemistry
Background:
- Human parainfluenza virus type 3 (HPF3) envelope glycoproteins, hemagglutinin-neuraminidase (HN) and fusion protein (F), mediate viral entry and cell-cell fusion.
- HN possesses both receptor-binding and neuraminidase activities, crucial for viral replication.
- Sialic acid-based inhibitors, such as 4-guanidino-neu5Ac2en (4-GU-DANA), have shown potential in inhibiting HPF3 neuraminidase activity, receptor binding, and fusion.
Purpose of the Study:
- To elucidate the mechanism by which 4-GU-DANA inhibits HPF3.
- To investigate the role of neuraminidase in the HPF3 viral life cycle.
- To assess the efficacy of 4-GU-DANA in counteracting HPF3 infection.
Main Methods:
- Utilized a neuraminidase-deficient HPF3 variant (C28a) and cell lines expressing wild-type (wt) or C28a HN.
- Assessed hemadsorption activity (HAD) and plaque enlargement in the presence and absence of 4-GU-DANA and exogenous neuraminidase.
- Monitored virion release and multicycle replication in infected cell monolayers.
Main Results:
- Cells expressing C28a HN exhibited temperature-dependent hemadsorption, inhibited by 4-GU-DANA, confirming its effect on receptor binding.
- 4-GU-DANA diminished plaque enlargement, indicating inhibition of HN's fusogenic function.
- Virion release and multicycle replication were severely restricted in C28a-infected cells, a defect rescued by exogenous neuraminidase or 4-GU-DANA.
- 4-GU-DANA's inhibition of viral entry and syncytium formation counteracts wt HPF3 infection.
Conclusions:
- 4-GU-DANA inhibits HPF3 by targeting both viral entry and cell-cell fusion.
- HPF3 neuraminidase activity is essential for efficient virion release and multicycle replication.
- Sialic acid analogs represent a promising therapeutic strategy against HPF3 infections.
More Related Videos
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
12:09Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Published on: November 22, 2017
Related Concept Videos
Leaky Scanning
Influenza
Inhibitors Of Virion Release